Not all IGHV3-21 chronic lymphocytic leukemias are equal: Prognostic considerations

Blood

Volumn 125, Issue 5, 2015, Pages 856-859

  Baliakas, Panagiotis ^a   Agathangelidis, Andreas ^b,c   Hadzidimitriou, Anastasia ^a,d   Sutton, Lesley Ann ^a   Minga, Eva ^d   Tsanousa, Athina ^e   Scarfò, Lydia ^b,c   Davis, Zadie ^f   Yan, Xiao Jie ^g   Shanafelt, Tait ^h   Plevova, Karla ⁱ   Sandberg, Yorick ^j   Vojdeman, Fie Juhl ^k   Boudjogra, Myriam ^l   Tzenou, Tatiana ^m   Chatzouli, Maria ⁿ   Chu, Charles C ^g   Veronese, Silvio ^o   Gardiner, Anne ^f   Mansouri, Larry ^a   Smedby, Karin E ^p   Pedersen, Lone Bredo ^k   Moreno, Denis ^q   Van Lom, Kirsten ^j   Giudicelli, Véronique ^q   Francova, Hana Skuhrova ⁱ   Nguyen Khac, Florence ^r   Panagiotidis, Panagiotis ^m   Juliusson, Gunnar ^s   Angelis, Lefteris ^e   Anagnostopoulos, Achilles ^t   Lefranc, Marie Paule ^q   Facco, Monica ^u,v   Trentin, Livio ^u,v   Catherwood, Mark ^w   Montillo, Marco ^o   Geisler, Christian H ^k   Langerak, Anton W ^j   Pospisilova, Sarka ⁱ   Chiorazzi, Nicholas ^g   Oscier, David ^f   Jelinek, Diane F ^x   Darzentas, Nikos ^y   Belessi, Chrysoula ⁿ   Davi, Frederic ^r   Ghia, Paolo ^b,c   Rosenquist, Richard ^a   Stamatopoulos, Kostas ^a,d,t   more..

^a UPPSALA UNIVERSITY   (Sweden)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^g FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k Rigshospitalet   (Denmark)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m UNIVERSITY OF ATHENS   (Greece)

ⁿ GENERAL HOSPITAL OF NIKEA   (Greece)

^o OSPEDALE NIGUARDA CA GRANDA   (Italy)

^p KAROLINSKA INSTITUTE   (Sweden)

^q UNIV MONTPELLIER   (France)

^r SORBONNE UNIVERSITÉ   (France)

^s LUND UNIVERSITY   (Sweden)

^t Papanicolaou General Hospital   (Greece)

^u UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^v VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^w BELFAST CITY HOSPITAL   (United Kingdom)

^x MAYO GRADUATE SCHOOL   (United States)

^y MASARYK UNIVERSITY   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMINO ACID COMPOSITION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; GENE MUTATION; HUMAN; IGHV3 21 GENE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR GENE; AGED; B LYMPHOCYTE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENETIC HETEROGENEITY; GENETICS; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SOMATIC HYPERMUTATION; SURVIVAL ANALYSIS; TIME TO TREATMENT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN HEAVY CHAIN;

AGED; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; GENETIC HETEROGENEITY; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; SURVIVAL ANALYSIS; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84921856679     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-600874     Document Type: Article

References (25)

1. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847.
2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854.
3. Hamblin TJ, Davis ZA, Oscier DG. Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia - long-term follow up of patients with different percentages of mutations. Br J Haematol. 2008;140(3):320-323.
4. Kröber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100(4):1410-1416.
5. Langerak AW, Davi F, Ghia P, et al; European Research Initiative on CLL (ERIC). Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases. Leukemia. 2011;25(6):979-984.
6. Ghia P, Stamatopoulos K, Belessi C, et al; European Research Initiative on CLL. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia. 2007;21(1):1-3.
7. Agathangelidis A, Vardi A, Baliakas P, Stamatopoulos K. Stereotyped B-cell receptors in chronic lymphocytic leukemia. Leuk Lymphoma. 2014;55(10):2252-2261.
8. Bomben R, Dal-Bo M, Benedetti D, et al. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. Clin Cancer Res. 2010;16(2):620-628.
9. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109(1):259-270.
10. Thorsélius M, Kröber A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood. 2006;107(7):2889-2894.
11. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood. 2003;101(12):4952-4957.
12. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 2002;99(6):2262-2264.
13. Bomben R, Dal Bo M, Capello D, et al. Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. Blood. 2007;109(7):2989-2998.
14. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood. 2005;105(4):1678-1685.
15. Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood. 2012;119(19):4467-4475.
16. Marincevic M, Cahill N, Gunnarsson R, et al. High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors. Haematologica. 2010;95(9):1519-1525.
17. Rossi D, Spina V, Bomben R, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood. 2013;121(24):4902-4905.
18. Strefford JC, Sutton LA, Baliakas P, et al. Distinct patterns of novel gene mutations in poorprognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia. 2013;27(11):2196-2199.
19. Cahill N, Sutton LA, Jansson M, et al. IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012; 12(3):201-206.
20. Ghia EM, Jain S, Widhopf GF II, et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008;111(10):5101-5108.
21. Baliakas P, Iskas M, Gardiner A, et al. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am J Hematol. 2014;89(3):249-255.
22. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008;111(3):1524-1533.
23. Thunberg U, Johnson A, Roos G, et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood. 2001;97(6):1892-1894.
24. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004;103(12):4389-4395.
25. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol. 2014;1(2):e74-e84.